NEUFELD, Austria, Feb. 25, 2025 /PRNewswire/ -- Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen, The Netherlands). The multicentric prospective...
Hence then, the article about sanochemia spl investigational iron based mri contrast agent meets primary endpoints in pivotal phase iii study was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study )
Also on site :
- 2000s Heavy Metal Band Shares Exciting Music Festival News
- Saudi to Sudan: Can Pakistan expand military footprint across Arab world?
- Iconic '80s Heavy Metal Band Announces 2026 North America Tour Dates